Utah Medical Products INC 8-K filings

Utah Medical Products, Inc. announced a revenue decline for the second quarter and first half of 2026 compared to the prior year, primarily due to the loss of sales to two major former customers.

Utah Medical Products, Inc. held its annual stockholder meeting on May 1, 2026, where key director elections and auditor ratification were approved.

Utah Medical Products, Inc. reported first quarter 2026 financial results consistent with projections, but showed a 10.2% decrease in revenue compared to the prior year, primarily due to the loss of a major China distributor.

Utah Medical Products, Inc. reported a decline in 2025 financial performance, missing projections, yet increased cash balances and raised its quarterly dividend.

Utah Medical Products, Inc. announced an increase in its quarterly cash dividend by 1.6% to $0.31 per share and appointed Kevin Timken to its expanded Board of Directors.

Utah Medical Products, Inc. reports a significant decline in third-quarter and nine-month 2025 financial results, primarily due to global trade uncertainty and distributor order cancellations.

Utah Medical Products, Inc. reported second quarter and first half 2025 financial results largely consistent with projections, marked by a significant decline in sales to its biopharma OEM customer PendoTECH, offset by robust domestic sales growth and a strong balance sheet.

Utah Medical Products held its annual meeting on May 2, 2025, where stockholders elected a director, ratified the selection of an accounting firm, and approved executive compensation.

Utah Medical Products' Q1 2025 financial results declined compared to Q1 2024, primarily due to a significant decrease in OEM sales to PendoTECH.

Utah Medical Products experienced a contraction in 2024, with revenues declining by 19% compared to the previous year.

Utah Medical Products has appointed a new director, Carrie Leigh, and increased its quarterly cash dividend by 1.7%.

Utah Medical Products experienced a decrease in revenue but improved profitability in the third quarter of 2024 compared to the same period last year.

Utah Medical Products experienced a significant revenue decline in the first half of 2024, primarily due to reduced sales to a major OEM customer and a Chinese distributor, but maintained strong profit margins.

Utah Medical Products, Inc. held its annual stockholder meeting on May 3, 2024, where directors were elected, the accounting firm was ratified, and executive compensation was approved on an advisory basis.

Utah Medical Products experienced a decrease in revenue and profitability in the first quarter of 2024, despite some positive developments in cost management and non-operating income.

Utah Medical Products experienced a 4% decrease in revenue but a 1% increase in net income and earnings per share for the full year 2023 compared to 2022.